Vaxart, Inc.
VXRT · Biological Products, (No Disgnostic Substances)
Latest available SEC filing: 4 ·
Latest disclosures
-
Bono Raquel C.: Form 4
Insider disclosure · Filed · Report period 16 Oct 2026
-
Form 3
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Latest financial period: Q2 2026
Financial facts · Filed
-
Form 10-Q
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- VXRT · 92243A200 - Common Stock, $0.0001 par value per share
Company details and SEC sources
CIK 0000072444 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- VXRT on OTC
- SEC industry group
- Biological Products, (No Disgnostic Substances) (Office of Life Sciences)
- Business address
- 310 Utah Avenue, Suite 150, South San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- 31 December
- Former names on EDGAR
-
Aviragen Therapeutics Inc. (to 15 Feb 2018) Biota Pharmaceuticals Inc. (to 13 Apr 2016) NABI BIOPHARMACEUTICALS (to 08 Nov 2012) NABI BIOPHARMACEUTICALS (to 29 Jun 2010) NABI /DE/ (to 14 Feb 2002) NORTH AMERICAN BIOLOGICALS INC (to 14 Feb 1996)
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields